GDF15 anticorps (C-Term)

N° du produit ABIN453961

L’anticorps anti-GDF15 Polyclonal Lapin est utilisé pour la détection de GDF15 dans des échantillons de Humain, Souris, Rat, Chimpanzé et Macaque. Il a été validé pour WB et EIA.

Aperçu rapide pour GDF15 anticorps (C-Term) (ABIN453961)

Antigène: GDF15 (Growth Differentiation Factor 15 (GDF15))

Reactivité: Humain, Souris, Rat, Chimpanzé, Macaque

Hôte: Lapin

Clonalité: Polyclonal

Conjugué: Cet anticorp GDF15 est non-conjugé

Application: Western Blotting (WB), Enzyme Immunoassay (EIA)

Détail du produit anti-GDF15 anticorps

Épitope: C-Term

Specificité: This antibody reacts with the C-terminus of endogenous NAG-1 protein.

Réactivité croisée (Details): Species reactivity (expected):Chimpanzee, Macaque, Mouse, Rat.
Species reactivity (tested):Human.

Purification: Affinity chromatography

Immunogène: Synthetic peptide corresponding to the C-terminal sequence of NAG-1 protein. A residue of cysteine was added to facilitate coupling

Isotype: IgG

Information d'application

Indications d'application: ELISA: 1/300,000. Western Blot: 2,000 - 10,000.

Restrictions: For Research Use only

Stockage

Format: Liquid

Concentration: 1.0 mg/mL (by UV absorbance at 280 nm)

Buffer: 0.02 M Potassium Phosphate, 0.15 M Sodium Chloride, pH 7.2 containing 0.09 % (w/v) Sodium

Agent conservateur: Sodium azide

Précaution d'utilisation: This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Conseil sur la manipulation: Avoid repeated freezing and thawing.

Stock: -20 °C

Détails sur GDF15

Antigène: GDF15 (Growth Differentiation Factor 15 (GDF15))

Autre désignation: GDF15

Sujet: The non-steroidal antiinflammatory drug (NSAID) activated gene (NAG-1) is a member of the transforming growth factor-beta (TGF-beta) superfamily. NAG-1 is also known as Macrophage Inhibitory Cytokine-1 (MIC-1), Growth Differentiation Factor 15 (GDF15), Placental Bone Morphogenetic Protein (PLAB), or Prostate Derived Factor (PDF). NAG-1 is expressed in human placenta, prostate and colon. It possesses antitumorigenic and proapoptotic activities. NAG-1 expression is dramatically increased in inflammation, injury and malignancy. Increase of NAG-1 expression is a feature of many cancers including breast, colon, pancreas and prostate. In a number of studies, NAG-1 expression was increased by a number of NSAIDs. This increase in expression may correlate with the chemopreventive effect NSAIDs seem to have with certain cancers. NAG-1 expression is also induced by PPAR gamma ligands and by several dietary compounds such as conjugated linoleic acids (CLAs), naturally occurring fatty acids in ruminant food products, indoles, epicatechin gallate, and genistein. The induced expression of NAG-1 results in a stimulation of apoptosis and inhibition of cell growth. Inhibition of NAG-1 induced expression by small interference RNA (siRNA) results in repression of induced apoptosis. NAG-1 expression is regulated by a numbers of transcription factors such as ERG-1 and Sp1. EGR-1 may be necessary for NSAID-induced NAG-1 expression. The study of expression of NAG-1 proteins, including variants, is important to define their potential role as serum biomarkers for cancer diagnosis, treatment monitoring, epidemiology study, and nutrition surveys.Synonyms: GDF-15, Growth/differentiation factor 15, MIC-1, MIC1, Macrophage inhibitory cytokine 1, NAG-1, NRG-1, NSAID-activated gene 1 protein, NSAID-regulated gene 1 protein, PDF, PLAB, PTGFB, Placental TGF-beta, Placental bone morphogenetic protein, Prostate differentiation factor

ID gène: 9518

NCBI Accession: NP_004855

UniProt: Q99988

Pathways: SARS-CoV-2 Protein Interactome